Shinji Uemoto M.D., Ph.D. Professor
In our division, we are practicing multi-modality treatments consisting of surgical operation and others for patients with hepato-biliary and pancreatic malignancies. We are undertaking extension of surgical indication based on the latest outcomes of clinical studies. Our practice includes minimally invasive surgery such as laparoscopic cholecystectomy, laparoscopic splenectomy, laparoscopic hepatectomy, and laparoscopic-robotic pancreatectomy for benign and malignant diseases. Our experience includes one of the largest series of living-donor liver transplantation (LDLT). It is our goal to produce leading surgeons through cutting edge researches and intensive training of surgical skills.
Research and EducationStudies on development of molecular-targeted therapy against hepatocellular carcinoma, mechanism of chemotherapy-induced liver injury, and molecular mechanism of liver fibrosis are conducted. We execute experiments for differentiation and cell transplantation of several kinds of stem/progenitor cells such as ES cells, iPS cells, hepatic stem cells, and hepatic progenitor cells. We focus on the identification and characterization of cancer stem cells of liver and pancreatic cancer. To improve clinical outcome of pancreatic cancer, we are actively undertaking the international collaborative study on precursors to pancreatic cancer or PanIN. We have islet transplantation program both in clinical practice and basic research. Development of “chimeric liver”, mesenchymal stem cell transplantation with liver transplantation, development of novel strategy/algorithm for intensive portal venous pressure, and development of a novel perfusion preservation of liver grafts by graft “Post-conditioning” are investigated. We support graduate students not only to laboratory research, but also to learn advanced medicine and to study abroad. Conferring the degree, they can play active parts in education, research and clinic.
Colocalization of SOX9 and CD44 expression in normal pancreas (A–D), IPMN (E–H), and PDAC (I–L)
Images show anti-SOX9 as red, anti-CD44 as green, and nuclear staining with Hoechst as blue. D, H, and L represent higher magnifications of the insets in C, G, and K, respectively. Nuclear counterstaining images are not included in D, H, and L in order to highlight nuclear SOX9 staining. Arrows indicate the colocalization of SOX9 and CD44 expression (D, H, L). （Pancreas. 2014;43:7-14）
Recent Publications1.Expression of SOX9 in intraductal papillary mucinous neoplasms of the pancreas. Meng F, Takaori K, Ito T, Masui T, Kawaguchi M, Kawaguchi Y, Uemoto S. Pancreas. 2014;43(1):7-14.
2.Impact of Hepatic Steatosis on Disease-Free Survival in Patients with Non-B Non-C Hepatocellular Carcinoma Undergoing Hepatic Resection. Nishio T, Hatano E, Sakurai T, Taura K, Okuno M, Kasai Y, Seo S, Yasuchika K, Mori A, Kaido T, Uemoto S. Ann Surg Oncol. 2015;22(7):2226-34.
3.Luminal injection of hydrogen-rich solution attenuates intestinal ischemia-reperfusion injury in rats. Shigeta T, Sakamoto S, Li XK, Cai S, Liu C, Kurokawa R, Nakazawa A, Kasahara M, Uemoto S. Transplantation. 2015;99(3):500-7.
4.Advantage of tacrolimus/mycophenolate mofetil regimen for cytotoxic T cell-mediated defence and its inhibition by additive steroid administration in high-risk liver transplant recipients. Uemoto S, Ozawa K, Kaido T, Mori A, Fujimoto Y. Clin Exp Immunol. 2016;184(1):126-36
5.How far can we lower graft-to-recipient weight ratio for living donor liver transplantation under modulation of portal venous pressure? Uemura T, Wada S, Kaido T, Mori A, Ogura Y, Yagi S, Fujimoto Y, Ogawa K, Hata K, Yoshizawa A, Okajima H, Uemoto S. Surgery. 2016;159(6):1623-30
Hepato- Biliary-Pancreatic Surgery and TransplantationProfessor ： Shinji Uemoto
Associate Professor ： Kyoichi Takaori・Toshimi Kaido・Hideaki Okajima
Senior Lecturer：Kojiro Taura・Kentaro Yasuchika
Assistant Professor：Toshihiko Masui・Koichiro Hata・Tomo Seo・Naoko Kamo・Shintaro Yagi・
Jun Yoshizawa・Takamichi Ishii・Ken Fukumitsu・Takao Ito・Takayuki Anazawa